Sun G - Researchers assessed renal cell carcinoma (RCC) progression and resistance to sunitinib in relation to adiponectin. Assays with RCC cell lines were used to assess the signal transduction pathways of adiponectin in RCC. Overall, 126 patients who received tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma (mRCC) were included. Tissue samples were analyzed using immunohistochemistry to determine tumor Adiponectine receptor 1 (AdipoR1) and Adiponectine receptor 2 (AdipoR2). Favorable response to TKI and good survival outcomes were significantly and independently predicted by AdipoR1 expression, but not AdipoR2. By blocking GSK3β and β-Catenin pathway, migration and invasion of RCC cells could be hindered by AdipoR1, which also inhibited AKT and NF-κB pathway and resulted in increased sensitivity of cells to sunitinib. AdipoR1 showed potential as a prognostic marker for favorable outcomes of mRCC patients.